Li Philip Kam-Tao, Chow Kai Ming, Cho Yeoungjee, Fan Stanley, Figueiredo Ana E, Harris Tess, Kanjanabuch Talerngsak, Kim Yong-Lim, Madero Magdalena, Malyszko Jolanta, Mehrotra Rajnish, Okpechi Ikechi G, Perl Jeff, Piraino Beth, Runnegar Naomi, Teitelbaum Isaac, Wong Jennifer Ka-Wah, Yu Xueqing, Johnson David W
Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Carol and Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
Perit Dial Int. 2022 Mar;42(2):110-153. doi: 10.1177/08968608221080586.
Peritoneal dialysis (PD)-associated peritonitis is a serious complication of PD and prevention and treatment of such is important in reducing patient morbidity and mortality. The ISPD 2022 updated recommendations have revised and clarified definitions for refractory peritonitis, relapsing peritonitis, peritonitis-associated catheter removal, PD-associated haemodialysis transfer, peritonitis-associated death and peritonitis-associated hospitalisation. New peritonitis categories and outcomes including pre-PD peritonitis, enteric peritonitis, catheter-related peritonitis and medical cure are defined. The new targets recommended for overall peritonitis rate should be no more than 0.40 episodes per year at risk and the percentage of patients free of peritonitis per unit time should be targeted at >80% per year. Revised recommendations regarding management of contamination of PD systems, antibiotic prophylaxis for invasive procedures and PD training and reassessment are included. New recommendations regarding management of modifiable peritonitis risk factors like domestic pets, hypokalaemia and histamine-2 receptor antagonists are highlighted. Updated recommendations regarding empirical antibiotic selection and dosage of antibiotics and also treatment of peritonitis due to specific microorganisms are made with new recommendation regarding adjunctive oral N-acetylcysteine therapy for mitigating aminoglycoside ototoxicity. Areas for future research in prevention and treatment of PD-related peritonitis are suggested.
腹膜透析(PD)相关腹膜炎是PD的一种严重并发症,其防治对于降低患者发病率和死亡率至关重要。国际腹膜透析学会(ISPD)2022年更新的建议修订并明确了难治性腹膜炎、复发性腹膜炎、与腹膜炎相关的导管拔除、PD相关血液透析转换、与腹膜炎相关的死亡以及与腹膜炎相关的住院治疗的定义。定义了新的腹膜炎类别和结局,包括PD前腹膜炎、肠道腹膜炎、导管相关腹膜炎和临床治愈。建议的总体腹膜炎发生率新目标应为每年每风险患者不超过0.40次发作,单位时间内无腹膜炎患者的百分比目标应为每年>80%。包括关于PD系统污染管理、侵入性操作的抗生素预防以及PD培训和重新评估的修订建议。强调了关于可改变的腹膜炎危险因素(如家养宠物、低钾血症和组胺-2受体拮抗剂)管理的新建议。对经验性抗生素选择和抗生素剂量以及特定微生物所致腹膜炎的治疗提出了更新建议,并提出了关于辅助口服N-乙酰半胱氨酸疗法减轻氨基糖苷类耳毒性的新建议。还提出了PD相关腹膜炎防治未来研究的领域。